Evommune, Inc.
For the period ended Sep 30, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Dec 11, 2025
EVMN$7.84+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
(In thousands, except share and per share amounts)
| September 30, · December 31, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 26,818 | $ | 16,255 |
| Short-term investments | 49,244 | 55,785 | ||
| Prepaid expenses and other current assets | 5,879 | 1,948 | ||
| Total current assets | 81,941 | 73,988 | ||
| Operating lease right-of-use assets, net | 160 | 472 | ||
| Property and equipment, net | 970 | 1,326 | ||
| Restricted cash | 1,412 | 208 | ||
| Other non-current assets | 61 | 61 | ||
| Total assets | $ | 84,544 | $ | 76,055 |
| Liabilities, Convertible Preferred Stock, and Stockholders’ Deficit | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 3,576 | $ | 8,264 |
| Accrued liabilities | 6,309 | 6,729 | ||
| Operating lease liability, current portion | 160 | 487 | ||
| Convertible preferred stock forward | — | 8,928 | ||
| Deferred revenue | — | 3,000 | ||
| Other current liabilities | 371 | 573 | ||
| Total current liabilities | 10,416 | 27,981 | ||
| Other non-current liabilities | 261 | 535 | ||
| Total liabilities | 10,677 | 28,516 | ||
| Commitments and contingencies (Note 6) | ||||
| Convertible preferred stock: $0.0001 par value — 157,657,729 shares authorized at September 30, 2025 and December 31, 2024, respectively, 157,657,729 and 116,716,142 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively (Liquidation preference $275,611 and $210,328 at September 30, 2025 and December 31, 2024, respectively) | 257,004 | 191,776 | ||
| Stockholders’ deficit: | ||||
| Common stock, par value $0.0001 — 223,593,879 shares authorized at September 30, 2025 and December 31, 2024, respectively; 1,554,965 and 1,551,420 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | — | — | ||
| Additional paid-in capital | 9,679 | 7,982 | ||
| Accumulated deficit | (192,816) | (152,219) | ||
| Total stockholders’ deficit | (183,137) | (144,237) | ||
| Total liabilities, convertible preferred stock, and stockholders’ deficit | $ | 84,544 | $ | 76,055 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.